

**Ovoca Bio plc**

**("Ovoca" or the "Company")**

**Sale of Treasury Shares**

Dublin, Ireland, 9 October 2024 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that it has transferred 6,895,000 ordinary shares of the Company out of treasury ("Treasury Shares"), and sold these shares in the market at an average price of approximately 1.01 pence per share, raising gross proceeds of £69,020.

Following the sale of the Treasury Shares, the Company has a total of 88,458,806 ordinary shares in issue, and there are no remaining shares held in treasury. Therefore, the figure of 88,458,806 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company.

**End**

For further information:

**Ovoca Bio plc**  
Tim McCutcheon (Chief Executive Officer)  
Tel +353 1 661 9819  
info@ovocabio.com

**Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)**  
Ivan Murphy / Daragh O'Reilly  
Tel: +353 1 679 6363

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISFZMGGVLFGDZM